[go: up one dir, main page]

WO2010067980A3 - 잠복성 ｈｉｖ 감염 세포에서 ｈｉｖ-1 프로바이러스를 재활성화시키는 히스톤 디아세틸라제 억제제 - Google Patents

잠복성 ｈｉｖ 감염 세포에서 ｈｉｖ-1 프로바이러스를 재활성화시키는 히스톤 디아세틸라제 억제제 Download PDF

Info

Publication number
WO2010067980A3
WO2010067980A3 PCT/KR2009/007162 KR2009007162W WO2010067980A3 WO 2010067980 A3 WO2010067980 A3 WO 2010067980A3 KR 2009007162 W KR2009007162 W KR 2009007162W WO 2010067980 A3 WO2010067980 A3 WO 2010067980A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
proviruses
inhibitor
infected cells
latently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/007162
Other languages
English (en)
French (fr)
Other versions
WO2010067980A2 (ko
Inventor
홍기종
최병선
김성순
이학성
노성구
현영란
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Centers for Disease Control and Prevention
Original Assignee
Korea Centers for Disease Control and Prevention
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Centers for Disease Control and Prevention filed Critical Korea Centers for Disease Control and Prevention
Priority to KR1020117012184A priority Critical patent/KR101388596B1/ko
Publication of WO2010067980A2 publication Critical patent/WO2010067980A2/ko
Publication of WO2010067980A3 publication Critical patent/WO2010067980A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본원 발명은 잠복성 HIV 감염 세포로부터 HIV-1 프로바이러스(HIV-1 provirus)를 재활성화시킬 수 있는 화학식 1의 히스톤 디아세틸라제(HDAC) 억제제 및 이 억제제를 사용하여 잠복성 HIV 감염 세포로부터 HIV-1 프로바이러스를 재활성화시키는 방법에 관한 것이다. 상기 HDAC 억제제는 낮은 세포 독성 및 높은 안정성을 나타내어, CD4+ T 세포 병원소로부터 잠복성 HIV-1 프로바이러스를 보다 효과적으로 재활성시킬 수 있는 것을 특징으로 한다. 이에 따라, 상기 HDAC 억제제를 역전사 효소 억제제인 AZT와 같은 HAART 칵테일 치료약물과 함께 처리하여, 잠복성 HIV 병원소를 효율적으로 감소 또는 제거시킬 수 있다.
PCT/KR2009/007162 2008-12-11 2009-12-02 잠복성 ｈｉｖ 감염 세포에서 ｈｉｖ-1 프로바이러스를 재활성화시키는 히스톤 디아세틸라제 억제제 Ceased WO2010067980A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020117012184A KR101388596B1 (ko) 2008-12-11 2009-12-02 잠복성 hiv 감염 세포에서 hiv-1 프로바이러스를 재활성화시키는 히스톤 디아세틸라제 억제제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12190108P 2008-12-11 2008-12-11
US61/121,901 2008-12-11

Publications (2)

Publication Number Publication Date
WO2010067980A2 WO2010067980A2 (ko) 2010-06-17
WO2010067980A3 true WO2010067980A3 (ko) 2010-09-23

Family

ID=42243170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/007162 Ceased WO2010067980A2 (ko) 2008-12-11 2009-12-02 잠복성 ｈｉｖ 감염 세포에서 ｈｉｖ-1 프로바이러스를 재활성화시키는 히스톤 디아세틸라제 억제제

Country Status (2)

Country Link
KR (1) KR101388596B1 (ko)
WO (1) WO2010067980A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105597090B (zh) * 2014-11-14 2022-08-23 中国科学院上海营养与健康研究所 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
KR101978364B1 (ko) * 2017-06-15 2019-05-14 크리스탈지노믹스(주) 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 또는 그 유도체의 약학적으로 허용 가능한 염 및 그 제조방법
EP3810755A4 (en) 2018-06-19 2021-12-01 Nantcell, Inc. COMPOSITIONS AND METHODS OF TREATMENT FOR HIV
KR102678356B1 (ko) * 2018-10-29 2024-06-26 씨지인바이츠 주식회사 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 인산염, 타르타르산염 또는 이들의 조합을 포함하는 약제학적 조성물 및 그 제조방법
KR20220118747A (ko) * 2021-02-19 2022-08-26 크리스탈지노믹스(주) 제2형 중증급성호흡기증후군 코로나바이러스 감염증 예방 또는 치료용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076386A2 (en) * 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
WO2007052938A1 (en) * 2005-11-01 2007-05-10 Korea Research Institute Of Chemical Technology Alkylcarbamoyl naphthalenyloxy- octenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and preparation thereof
WO2008068170A1 (en) * 2006-12-04 2008-06-12 William Paul Jackson Hdac inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076386A2 (en) * 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
WO2007052938A1 (en) * 2005-11-01 2007-05-10 Korea Research Institute Of Chemical Technology Alkylcarbamoyl naphthalenyloxy- octenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and preparation thereof
WO2008068170A1 (en) * 2006-12-04 2008-06-12 William Paul Jackson Hdac inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YLISASTIGUI, LOYDA ET AL.: "Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression", AIDS, vol. 18, no. ISSUE, 21 May 2004 (2004-05-21), pages 1101 - 1108 *

Also Published As

Publication number Publication date
WO2010067980A2 (ko) 2010-06-17
KR101388596B1 (ko) 2014-04-24
KR20110096028A (ko) 2011-08-26

Similar Documents

Publication Publication Date Title
WO2010067980A3 (ko) 잠복성 ｈｉｖ 감염 세포에서 ｈｉｖ-1 프로바이러스를 재활성화시키는 히스톤 디아세틸라제 억제제
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
TN2010000212A1 (en) Inhibitors of human immunodeficiency virus replication
EA201390794A1 (ru) Бициклическое соединение
EA201170960A1 (ru) Твердая фармацевтическая композиция, содержащая амлодипин и лозартан
EA200801144A1 (ru) Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
EP1564210A4 (en) 4-OXOCHINOLINE COMPOUNDS AND THEIR USE AS HIV INTEGRASE INHIBITORS
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
UA97834C2 (ru) Производные сульфониламида для лечения анормального роста клеток
EA200500322A1 (ru) Соединения дигидропиразолопиридина
EA201300902A1 (ru) Гранулы гамма-гидроксимасляной кислоты
EA201200552A1 (ru) Производные пиримидина в качестве ингибиторов протеинтирозинкиназы 2
MX2009013349A (es) Compuestos quimicos.
ZA200709481B (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
EA201101397A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201170979A1 (ru) Карбоксамидные соединения и способы их применения
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
EA201490223A1 (ru) Составы на основе дарунавира
IL180495A (en) Benzyl triazolone compounds as non-nucleotide reverse transcriptase inhibitors
TW200603783A (en) Non-nucleoside reverse transcriptase inhibitors
EA201071367A1 (ru) Соли соединений ингибиторов вич
WO2008122534A3 (en) Non-nucleoside reverse transcriptase inhibitors
MX2009012704A (es) Inhibidores de transcriptasa inversa de no nucleosidos.
WO2014201426A3 (en) Triazol-1-ol analogs anti-retroviral latency drugs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09832066

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 20117012184

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09832066

Country of ref document: EP

Kind code of ref document: A2